GlassScriptPhysician profile
Martha D Pilchman
NPI 1104923002
$5,783.18
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,637 · 2020: $1,092 · 2021: $893 · 2022: $1,160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $753.29 | 2019-2022 | |
| Amgen INC. | $699.30 | 2019-2022 | |
| Amarin Pharma, INC. | $574.09 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $559.01 | 2019-2022 | |
| Abbvie INC. | $415.44 | 2019-2021 | |
| Lilly USA, LLC | $334.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $243.31 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $171.77 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $169.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $144.59 | 2019-2020 | |
| Pfizer INC. | $120.13 | 2019-2022 | |
| Novo Nordisk INC | $112.91 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.53 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $67.70 | 2019-2020 | |
| Allergan, INC. | $64.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.63 | 2019-2020 | |
| Astellas Pharma US INC | $39.83 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $39.63 | 2019 | |
| Vivus LLC | $38.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.46 | 2022 | |
| Daiichi Sankyo INC. | $30.99 | 2022 | |
| Si-Bone, INC. | $19.79 | 2021 | |
| Esperion Therapeutics, INC. | $14.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Pilchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.